Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Design of Small Non-Peptidic Ligands That Alter Heteromerization between Cannabinoid CB and Serotonin 5HT Receptors

  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Ciruela-Jardí, Marc|||0009-0001-9920-8789
  • Gallo, Maria|||0000-0001-9099-7235
  • Ferré, Sergi|||0000-0002-1747-1779
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Moreno, Estefanía|||0000-0002-2491-5753
Activation of cannabinoid CB receptors (CBR) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CBR and the serotonin 5HT receptor (5HTR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CBR, which are predicted to bind 5HTR and alter the stability of the CBR-5HTR heteromer, have been shown to avert CBR agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CBR-5HTR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CBR-5HTR heteromer, opening new perspectives for in vivo studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo preliminar (WorkingPaper)

Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone

  • Michaelides, Michael|||0000-0003-0398-4917
  • Levinstein, Marjorie|||0000-0003-4360-1503
  • De Oliveira, Paulo
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Quiroz, Cesar
  • Budinich, Reece
  • Rais, Rana
  • Rea, William
  • Ventriglia, Emilya
  • Llopart, Natàlia
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Walther, Donna
  • Glatfelter, Grant
  • Weinshenker, David|||0000-0002-3678-6215
  • Zarate, Carlos
  • Casadó, Vicent|||0000-0002-1764-3825
  • Baumann, Michael
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Ferré, Sergi|||0000-0002-1747-1779
(R,S)-methadone ((R,S)-MTD) is a racemic μ-opioid receptor (MOR) agonist comprised of (R)-MTD and (S)-MTD enantiomers used for the treatment of opioid use disorder (OUD) and pain. (R)-MTD is used as an OUD treatment, has high MOR potency, and is believed to mediate (R,S)-MTD's therapeutic efficacy. (S)-MTD is in clinical development as an antidepressant and is considered an N-methyl-D-aspartate receptor (NMDAR) antagonist. In opposition to this purported mechanism of action, we found that (S)-MTD does not occupy NMDARs in vivo in rats. Instead, (S)-MTD produced MOR occupancy and induced analgesia with similar efficacy as (R)-MTD. Unlike (R)-MTD, (S)-MTD was not self-administered and failed to increase locomotion or extracellular dopamine levels indicating low abuse liability. Moreover, (S)-MTD antagonized the effects of (R)-MTD in vivo and exhibited unique pharmacodynamic properties, distinct from those of (R)-MTD. Specifically, (S)-MTD acted as a MOR partial agonist with a specific loss of efficacy at the MOR-galanin 1 receptor (Gal1R) heteromer, a key mediator of the dopaminergic effects of opioids. In sum, we report novel and unique pharmacodynamic properties of (S)-MTD that are relevant to its potential mechanism of action and therapeutic use, as well as those of (R,S)-MTD.